Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.
about
HIV-Associated Pneumocystis PneumoniaPneumocystis jirovecii Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis RecommendationsPneumocystis Pneumonia in Human Immunodeficiency Virus-infected Adults and Adolescents: Current Concepts and Future DirectionsTetrahydrobiopterin biosynthesis as an off-target of sulfa drugsSevere Pneumocystis jirovecii pneumonia in an idiopathic CD4+ lymphocytopenia patient: case report and review of the literature.How Clinically Relevant is Dapsone-related Peripheral Neuropathy?: An Overview of Available Data with Emphasis on Clinical Recognition.All-trans retinoic acid in combination with primaquine clears pneumocystis infectionPathological and protective immunity to Pneumocystis infection.Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.Colonization by Pneumocystis jirovecii and its role in disease.A protracted course of Pneumocystis pneumonia in the setting of an immunosuppressed child with GMS-negative bronchoalveolar lavageClinical and translational research in pneumocystis and pneumocystis pneumonia.Detection of Pneumocystis jirovecii by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients.Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realizedPneumocystis infection in humans: diagnosis and treatment.Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome.Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis.Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014.ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients.Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.Fatal Pneumocystis jirovecii pneumonia in a HIV-negative adult.Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients.Synthesis of [13C6]primaquine.Potential of bisbenzimidazole-analogs toward metronidazole-resistant Trichomonas vaginalis isolates.Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole used as First-Line Treatment for Pneumocystis jirovecii Pneumonia.Seasonal variation in mortality of Pneumocystis jirovecii pneumonia in HIV-infected patients
P2860
Q22241388-DFAE0564-F796-49EA-9886-16E1D1DBC9D1Q26781920-00AF6170-0E15-4E4B-93F4-DF30FA400A20Q26795592-115774E4-2702-40B0-8979-C431D3E9AC92Q27684698-452F3CF5-780F-4C05-A412-5F4E6D7C696CQ33635195-1D8C0E68-94A9-4FBB-8E19-2A092EE8E064Q33666873-D0F9CFBD-E73D-49D8-9761-85AE8488C87CQ34545112-078B68F2-9B05-440F-9BA2-E266A652ADF3Q35084980-D77701CE-7BE5-48CA-89B5-578BC914FE4BQ35692811-AA6AEBFA-6BEF-485F-8F48-D8F733E352A3Q35940586-ADB46489-310D-4356-B399-8981F3FDDFB5Q36871231-C1E07783-9AAB-49FF-9F0B-FC86855B2786Q36899081-AE318381-9914-4C18-AF9B-8EACAB1F5158Q36933191-005A2A4B-1E0F-45CE-B87F-AC59E8430F2CQ37180338-E761590D-2D21-4306-A0CC-C0C24863BA6FQ37393668-98A92EE0-CD98-4385-829D-52108C2B8E76Q37762544-C6678DAB-C657-48E9-A926-248F332364C2Q38039139-87E95AEF-B3D2-4045-B35F-2405EC23F062Q38245616-BF6A7B24-12B8-416D-A7AB-7F8221CC16B4Q38284466-B14362A6-C6CB-457A-B8B7-14C76729C40CQ38934528-38A703E7-CFD6-4987-A61D-238564DCD93CQ40092648-A48D7FDB-95B2-4B17-9311-868754141349Q40141721-A1201B26-59CC-4B6F-B5BE-97AE92F08BC4Q45070975-55B50968-E3AB-4A5C-9F66-FE60E89A4568Q45580143-332D3CBC-A17B-4531-A2C1-B18053679396Q48122716-493CFCEC-A777-4822-ACE1-11AE57C4E7E9Q55519151-41250BA2-9D9F-436D-AE8B-7FCF9ECF9ED5Q57586379-8C3E8627-AE70-49AC-8F72-7D63DF804FDF
P2860
Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical efficacy of first- an ...... ia: a tri-centre cohort study.
@en
Clinical efficacy of first- an ...... ia: a tri-centre cohort study.
@nl
type
label
Clinical efficacy of first- an ...... ia: a tri-centre cohort study.
@en
Clinical efficacy of first- an ...... ia: a tri-centre cohort study.
@nl
prefLabel
Clinical efficacy of first- an ...... ia: a tri-centre cohort study.
@en
Clinical efficacy of first- an ...... ia: a tri-centre cohort study.
@nl
P2093
P2860
P356
P1476
Clinical efficacy of first- an ...... ia: a tri-centre cohort study.
@en
P2093
Chiara Atzori
Jannik Helweg-Larsen
Robert F Miller
Thomas Benfield
P2860
P304
P356
10.1093/JAC/DKP372
P407
P577
2009-10-26T00:00:00Z